Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMARIN CORP PLC\UKAMRN · Entity 5970 | Director | June 27, 2022 | June 30, 2022 |
| CTS CORPCTS · Entity 4654 | Director | November 06, 2025 | November 10, 2025 |
| ELI LILLY & CoLLY · Entity 2794 | SVP & President, Lilly Int'l | February 08, 2021 | February 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMARIN CORP PLC\UK
Report date June 27, 2022 · Filed June 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2032-06-27 | Direct | 115,919 |
Reported balance
After 2022-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-27 · Grant · Acquired 115,919 · Balance 115,919 F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 93,750 |
Reported balance
After 2022-06-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-27 · Grant · Acquired 93,750 · Balance 93,750 F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year. F5: Not applicable. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer.
F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year.
F5: Not applicable.
CTS CORP
Report date November 06, 2025 · Filed November 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,913 |
Reported balance
After 2025-11-06 transaction · row 1
1 source rowRow 1 · 2025-11-06 · Grant · Acquired 3,500 · Balance 35,913 F1: Restricted stock units vest 100% on the first anniversary of the grant date, contingent upon the recipient's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units vest 100% on the first anniversary of the grant date, contingent upon the recipient's continued service as a director through the vesting date.
ELI LILLY & Co
Report date February 08, 2021 · Filed February 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,947 |
Reported balance
After 2021-02-08 transaction · row 1
1 source rowRow 1 · 2021-02-08 · Grant · Acquired 29,037 · Balance 56,947 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2022-02-01 | Direct | 10,706 |
Reported balance
After 2021-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-08 · Grant · Acquired 10,706 · Balance 10,706 F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 4,667 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,667 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Calidi Biotherapeutics, Inc.
Report date December 21, 2023 · Filed January 05, 2024
Section 16 reporting ended · disclosed 2024-01-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,301 |
Reported balance
After 2023-12-21 transaction · row 1
1 source rowRow 1 · 2023-12-21 · Grant · Acquired 5,644 · Balance 133,301 F1: Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date. As previously reported, Mr. Alfonso resigned as a director on November 29, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date. As previously reported, Mr. Alfonso resigned as a director on November 29, 2023.
Syneos Health, Inc.
Report date September 28, 2023 · Filed September 28, 2023
Section 16 reporting ended · disclosed 2023-09-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-09-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-09-28 · Disposition to issuer · Disposed 3,493 · Balance 4,863 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. Row 2 · 2023-09-28 · Disposition to issuer · Disposed 4,863 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes.
F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals,
F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 06, 2025 Filed Nov 10, 2025 21:11 UTC | CTS CORP CTS · Entity 4654 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000026058-25-000025 · form4.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,913 F1 · shares: Restricted stock units vest 100% on the first anniversary of the grant date, contingent upon the recipient's continued service as a director through the vesting date. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:16 UTC | CTS CORP CTS · Entity 4654 | GrantCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-124105 · ownership.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,413 F1 · shares: Time based RSUs generally vesting on the first anniversary of the grant date. Read SEC document |
| December 21, 2023 Filed Jan 5, 2024 00:55 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantCommon Stock | 5,644 | $1.80 | $10,159.20 |
DisclosureSEC source: 0001493152-24-001138 · ownership.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,301 F1 · shares: Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date. As previously reported, Mr. Alfonso resigned as a director on November 29, 2023. Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 17:38 UTC | CTS CORP CTS · Entity 4654 | GrantCommon Stock | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054464 · doc4.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,013 F1 · shares: Time based RSUs generally vesting on the first anniversary of the grant date. Read SEC document |
| September 28, 2023 Filed Sep 28, 2023 17:08 UTC | Syneos Health, Inc. SYNH · Entity 109360 | Disposition to issuerClass A Common Stock | 4,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050777 · doc4.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2 · price: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3 · price: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time. Read SEC document |
| September 28, 2023 Filed Sep 28, 2023 17:08 UTC | Syneos Health, Inc. SYNH · Entity 109360 | Disposition to issuerClass A Common Stock | 3,493 | $43.00 | $150,199.00 |
DisclosureSEC source: 0001209191-23-050777 · doc4.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,863 F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. Read SEC document |
| May 25, 2023 Filed May 30, 2023 21:19 UTC | Syneos Health, Inc. SYNH · Entity 109360 | GrantClass A Common Stock | 4,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033057 · doc4.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,356 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the 2024 annual meeting of stockholders but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 20:24 UTC | CTS CORP CTS · Entity 4654 | GrantCommon Stock | 3,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-056546 · doc4.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,413 F1 · shares: Time based RSUs generally vesting on the first anniversary of the grant date. Read SEC document |
| June 27, 2022 Filed Jun 30, 2022 00:08 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 93,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005407 · primarydocument.xml · derivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Ordinary Shares · 93,750 shares Expires not disclosed F3 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 27, 2022 Filed Jun 30, 2022 00:08 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (Right to Buy) · Derivative | 115,919 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001562180-22-005407 · primarydocument.xml · derivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,919 Underlying: Ordinary Shares · 115,919 shares Expires 2032-06-27 F1 · derivative.exercise_date: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 25, 2022 Filed May 27, 2022 17:13 UTC | Syneos Health, Inc. SYNH · Entity 109360 | GrantClass A Common Stock | 2,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032651 · doc4.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,493 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document |
| May 16, 2022 Filed May 21, 2022 00:25 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 180,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004317 · primarydocument.xml · derivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Ordinary Shares · 180,000 shares Expires not disclosed F3 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F4 · derivative.exercise_date: On May 16, 2022, the Reporting Person was granted 180,000 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the anniversary of the grant date of May 16, 2022. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 16, 2022 Filed May 21, 2022 00:25 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (Right to Buy) · Derivative | 223,719 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001562180-22-004317 · primarydocument.xml · derivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,719 Underlying: Ordinary Shares · 223,719 shares Expires 2032-05-16 F1 · derivative.exercise_date: On May 16, 2022, the Reporting Person was granted an option to purchase 223,719 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the one-year anniversary of the grant date of May 16, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 17:13 UTC | Syneos Health, Inc. SYNH · Entity 109360 | GrantClass A Common Stock | 654 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004093 · doc4.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 18:52 UTC | CTS CORP CTS · Entity 4654 | GrantCommon Stock | 3,600 | $36.69 | $132,084.00 |
DisclosureSEC source: 0001209191-21-063091 · doc4.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,313 F1 · shares: Time based shares vesting on the first anniversary of the grant date. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:53 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 10,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000072 · wf-form4_161300839694269.xml · derivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,706 Underlying: Common Stock · 10,706 shares Expires 2022-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:53 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 29,037 | $205.77 | $5,974,943.49 |
DisclosureSEC source: 0000059478-21-000072 · wf-form4_161300839694269.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,947 Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 16,754 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000036 · wf-form4_161239834705746.xml · derivative · entry 4 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,754 shares Expires 2021-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 7,490 | $207.97 | $1,557,695.30 |
DisclosureSEC source: 0000059478-21-000036 · wf-form4_161239834705746.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,910 Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 16,754 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000036 · wf-form4_161239834705746.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:24 UTC | CTS CORP CTS · Entity 4654 | GrantCommon | 4,200 | $29.23 | $122,766.00 |
DisclosureSEC source: 0001596336-20-000005 · wf-form4_160469785182075.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,713 F1 · shares: Time based shares vesting on the first anniversary of the grant date. F2 · balance_after: Total updated to reflect the initial 2,500 shares reported by the filing person on the Form 3 filed on April 18, 2018. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 17:43 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 11,000 | $170.00 | $1,870,000.00 |
DisclosureSEC source: 0000059478-20-000123 · wf-form4_159466220506801.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,646 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2020 and amended on June 11, 2020. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 13:36 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 10,000 | $165.00 | $1,650,000.00 |
DisclosureSEC source: 0000059478-20-000119 · wf-form4_159248735208255.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,646 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2020 and amended on June 11, 2020. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 13:36 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 7,000 | $160.00 | $1,120,000.00 |
DisclosureSEC source: 0000059478-20-000119 · wf-form4_159248735208255.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,646 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2020 and amended on June 11, 2020. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:52 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 10,000 | $150.00 | $1,500,000.00 |
DisclosureSEC source: 0000059478-20-000112 · wf-form4_159173595632339.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,646 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2020. Read SEC document |
| March 13, 2020 Filed Mar 13, 2020 15:02 UTC | CTS CORP CTS · Entity 4654 | PurchaseCommon | 940 | $22.17 | $20,839.80 |
DisclosureSEC source: 0001596336-20-000004 · wf-form4_158411171505169.xml · nonDerivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,013 Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 15:02 UTC | CTS CORP CTS · Entity 4654 | PurchaseCommon | 863 | $21.59 | $18,632.17 |
DisclosureSEC source: 0001596336-20-000004 · wf-form4_158411171505169.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,073 Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 15:02 UTC | CTS CORP CTS · Entity 4654 | PurchaseCommon | 860 | $23.45 | $20,167.00 |
DisclosureSEC source: 0001596336-20-000004 · wf-form4_158411171505169.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,210 Read SEC document |
| March 10, 2020 Filed Mar 10, 2020 20:09 UTC | CTS CORP CTS · Entity 4654 | PurchaseCommon | 850 | $23.51 | $19,983.50 |
DisclosureSEC source: 0001596336-20-000002 · wf-form4_158387093871232.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,350 Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:09 UTC | CTS CORP CTS · Entity 4654 | PurchaseCommon | 900 | $22.19 | $19,971.00 |
DisclosureSEC source: 0001596336-20-000002 · wf-form4_158387093871232.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:25 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 16,754 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000052 · wf-form4_158163631047243.xml · derivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,754 Underlying: Common Stock · 16,754 shares Expires 2021-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:25 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 18,322 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000052 · wf-form4_158163631047243.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,646 Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:59 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 16,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000022 · wf-form4_158084994011889.xml · derivative · entry 4 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,317 shares Expires 2020-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:59 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 7,299 | $139.64 | $1,019,232.36 |
DisclosureSEC source: 0000059478-20-000022 · wf-form4_158084994011889.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,324 Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:59 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 16,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000022 · wf-form4_158084994011889.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 21:37 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 4,500 | $120.00 | $540,000.00 |
DisclosureSEC source: 0000059478-19-000318 · wf-form4_157592745258343.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,306 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2019. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 14:33 UTC | CTS CORP CTS · Entity 4654 | GrantCommon | 4,400 | $27.81 | $122,364.00 |
DisclosureSEC source: 0000026058-19-000086 · wf-form4_157322360908494.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,600 F1 · shares: Time based shares vesting on the first anniversary of the grant date. Read SEC document |
| September 20, 2019 Filed Sep 23, 2019 19:54 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 4,500 | $117.00 | $526,500.00 |
DisclosureSEC source: 0000059478-19-000258 · wf-form4_156926846251839.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,806 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2019. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 19:09 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 19,500 | $112.91 | $2,201,745.00 |
DisclosureSEC source: 0000059478-19-000242 · wf-form4_156762415693254.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,306 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $112.54 to $113.85. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 9, 2019 15:59 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 4,500 | $112.54 | $506,430.00 |
DisclosureSEC source: 0000059478-19-000246 · wf-form4a_156804473200793.xml · nonDerivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,306 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2019. F4 · price: This transaction is being amended to correct the total number of shares and price previously reported as part of multiple trades on the Form 4 filed on 09/04/19. This transaction was executed in one trade at a price of $112.54. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 9, 2019 15:59 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 3,808 | $113.69 | $432,931.52 |
DisclosureSEC source: 0000059478-19-000246 · wf-form4a_156804473200793.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,806 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2019. F3 · price: This transaction is being amended to correct the price range reported on the Form 4 filed on 09/04/19. This transaction was executed in multiple trades at prices ranging from $113.50 to $113.85. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 9, 2019 15:59 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 11,192 | $112.88 | $1,263,352.96 |
DisclosureSEC source: 0000059478-19-000246 · wf-form4a_156804473200793.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,614 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2019. F2 · price: This transaction is being amended to correct the price range reported on the Form 4 filed on 09/04/19. This transaction was executed in multiple trades at prices ranging from $112.50 to $113.49. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 12, 2019 Filed Apr 16, 2019 18:48 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 10,000 | $124.65 | $1,246,500.00 |
DisclosureSEC source: 0000059478-19-000157 · wf-form4_155544046907704.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,806 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $124.22 to $125.00. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:58 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 16,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000067 · wf-form4_154950111330041.xml · derivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,317 Underlying: Common Stock · 16,317 shares Expires 2020-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:58 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 21,224 | $120.17 | $2,550,488.08 |
DisclosureSEC source: 0000059478-19-000067 · wf-form4_154950111330041.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,806 Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:09 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 9,722 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000042 · wf-form4_154941175147496.xml · derivative · entry 4 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,722 shares Expires 2019-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:09 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,364 | $119.86 | $523,069.04 |
DisclosureSEC source: 0000059478-19-000042 · wf-form4_154941175147496.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,582 Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:09 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 9,722 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000042 · wf-form4_154941175147496.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:32 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 4,000 | $120.00 | $480,000.00 |
DisclosureSEC source: 0000059478-19-000028 · wf-form4_154931592950395.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,224 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2018. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 22:16 UTC | CTS CORP CTS · Entity 4654 | GrantCommon | 4,200 | $28.85 | $121,170.00 |
DisclosureSEC source: 0000026058-18-000109 · wf-form4_154180178446099.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,200 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.